Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$343.34
+3.2%		$346.14
$136.73
▼
$382.54
$9.85B0.53557,676 shs162,831 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+3.16%+3.15%+1.21%+12.86%+138.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$343.34
+3.2%		$346.14
$136.73
▼
$382.54
$9.85B0.53557,676 shs162,831 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+3.16%+3.15%+1.21%+12.86%+138.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.92
Moderate Buy$365.406.43% Upside

Current Analyst Ratings Breakdown

Latest KRYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
8/14/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$400.00
8/14/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$400.00
8/4/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$378.00 ➝ $386.00
8/3/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
8/3/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/14/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$364.00 ➝ $396.00
7/13/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$474.00
7/1/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
6/18/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$306.00 ➝ $403.00
(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$389.13M26.12$7.52 per share45.66$45.92 per share7.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.9843.0336.80N/A54.82%19.34%17.65%11/2/2026 (Estimated)

Latest KRYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/3/2026Q2 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.70$1.79+$0.09$1.79$120.93 million$119.22 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
8.32
7.96

Institutional Ownership

CompanyInstitutional Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%

Insider Ownership

CompanyInsider Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21029.60 million25.72 millionOptionable

Recent News About These Companies

TimesSquare Capital Management LLC Makes New Investment in Krystal Biotech, Inc. $KRYS
August 18 at 5:44 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-timessquare-capital-management-llc-makes-new-investment-in-krystal-biotech-inc-krys-2026-08-18/
Krystal Biotech (KRYS) Has a New Rating from RBC Capital
August 17 at 7:58 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/KRYS/pressreleases/3867676/krystal-biotech-krys-has-a-new-rating-from-rbc-capital/
Krystal Biotech (NASDAQ:KRYS) Earns Moderate Buy Rating from Analysts at Royal Bank Of Canada
August 17 at 1:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30965124
State of Wyoming Buys New Stake in Krystal Biotech, Inc. $KRYS
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-state-of-wyoming-buys-new-stake-in-krystal-biotech-inc-krys-2026-08-16/
Krystal Biotech (NASDAQ:KRYS) Upgraded to "Moderate Buy" at Royal Bank Of Canada
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/krystal-biotech-nasdaqkrys-upgraded-to-moderate-buy-at-royal-bank-of-canada-2026-08-15/
Krystal Biotech (NASDAQ:KRYS) Director Sells 25,000 Shares
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-krys-insider-buying-and-selling-2026-08-15/
Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/dino-rossi-sells-25000-shares-of-krystal-biotech-nasdaqkrys-stock-2026-08-14/
Here are Friday’s top Wall Street analyst research calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, SanDisk, T-Mobile US, Wayfair, and ...
August 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/here-are-friday-s-top-wall-street-analyst-research-calls-cinemark-digital-realty-fox-corporation-krystal-biotech-ltc-properties-roku-sandisk-t-mobile-us-wayfair-and-more/ar-AA2a6mHL
Bank of America Corp DE Increases Stock Position in Krystal Biotech, Inc. $KRYS
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-increases-stock-position-in-krystal-biotech-inc-krys-2026-08-11/
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/krystal-biotech-krys-q2-2026-013254000.html
Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-has-248-million-stock-position-in-krystal-biotech-inc-krys-2026-08-10/
Krystal Biotech (NASDAQ:KRYS) Upgraded at Chardan Capital
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/krystal-biotech-nasdaqkrys-upgraded-at-chardan-capital-2026-08-06/
California State Teachers Retirement System Has $6.76 Million Holdings in Krystal Biotech, Inc. $KRYS
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-has-676-million-holdings-in-krystal-biotech-inc-krys-2026-08-06/
Citi Reaffirms Their Buy Rating on Krystal Biotech (KRYS)
August 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/KRYS/pressreleases/3664682/citi-reaffirms-their-buy-rating-on-krystal-biotech-krys/
Krystal Biotech, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931301-krystal-biotech-inc-2026-q2-results-earnings-call-presentation
Krystal Biotech, Inc. Q2 2026 Earnings Call Summary
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/krystal-biotech-inc-q2-2026-123000435.html
Krystal Biotech Earnings Call Signals Profitable Growth
August 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/krystal-biotech-earnings-call-signals-profitable-growth?utm_source=marketbeat.com&utm_medium=referral
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
August 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2967650/krystal-q2-earnings-sales-beat-estimates-pipeline-in-focus?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2967650
Brokers Issue Forecasts for Krystal Biotech FY2026 Earnings
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/brokers-issue-forecasts-for-krystal-biotech-fy2026-earnings-2026-08-04/
The Manufacturers Life Insurance Company Cuts Stake in Krystal Biotech, Inc. $KRYS
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-cuts-stake-in-krystal-biotech-inc-krys-2026-08-04/
Krystal Biotech (KRYS) Q2 2026 Earnings
August 3, 2026  |  247wallst.comhttps://247wallst.com/cards/krystal-biotech-q2-2026-earnings-krys-01kz3mxcnsdvypkb0ft3cpz8h9

New MarketBeat Followers Over Time

Media Sentiment Over Time

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$343.34 +10.52 (+3.16%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$335.26 -8.08 (-2.35%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas